التفاصيل البيبلوغرافية
| العنوان: |
Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters. |
| المؤلفون: |
Kim, Julius Woongki, Auffinger, Brenda, Spencer, Drew A., Miska, Jason, Chang, Alan L., Kane, Joshua Robert, Young, Jacob S., Kanojia, Deepak, Jian Qiao, Mann, Jill F., Lingjiao Zhan, Meijing Wu, Ahmed, Atique U., Aboody, Karen S., Strong, Theresa V., Hébert, Charles D., Lesniak, Maciej S., Qiao, Jian, Zhang, Lingjiao, Wu, Meijing |
| المصدر: |
Journal of Translational Medicine; 5/16/2016, Vol. 14, p1-14, 14p |
| مصطلحات موضوعية: |
HAMSTERS, MURIDAE, COMMON hamsters, DWARF hamsters, MESOCRICETUS, RNA metabolism, DNA analysis, ANIMALS, BIOLOGICAL models, BODY weight, BRAIN, FOOD habits, GENES, GENOMES, IMMUNE response, IMMUNOCOMPETENT cells, IMMUNOGLOBULINS, INFLAMMATION, RESEARCH funding, RNA, RODENTS, VIRUSES, ANTIBODY formation, INTRAVENTRICULAR injections |
| مستخلص: |
Background: CRAd-S-pk7 is a conditionally replicative oncolytic adenoviral vector that contains a survivin promoter and a pk7 fiber modification that confer tumor-specific transcriptional targeting and preferential replication in glioma while sparing the surrounding normal brain parenchyma.Methods: This IND-enabling study performed under GLP conditions evaluated the toxicity and biodistribution of CRAd-S-pk7 administered as a single intracerebral dose to Syrian hamsters, a permissive model of adenoviral replication. Two hundred and forty animals were stereotactically administered either vehicle (n = 60) or CRAd-S-pk7 at 2.5 × 10(7), 2.5 × 10(8), or 2.5 × 10(9) viral particles (vp)/animal (each n = 60) on day 1. The animals were closely monitored for toxicology evaluation, assessment of viral distribution, and immunogenicity of CRAd-S-pk7.Results: Changes in hematology, clinical chemistry, and coagulation parameters were minor and transient, and consistent with the inflammatory changes observed microscopically. These changes were considered to be of little toxicological significance. The vector remained localized primarily in the brain and to some degree in the tissues at the incision site. Low levels of vector DNA were detected in other tissues in a few animals suggesting systemic circulation of the virus. Viral DNA was detected in brains of hamsters for up to 62 days. However, microscopic changes and virus-related toxicity to the central nervous system were considered minor and decreased in incidence and severity over time. Such changes are not uncommon in studies using adenoviral vectors.Conclusion: This study provides safety and toxicology data justifying a clinical trial of CRAd-S-pk7 loaded in FDA-approved HB1.F3.CD neural stem cell carriers administered at the tumor resection bed in humans with recurrent malignant glioma. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Translational Medicine is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder